2007 forecast

In 2007, revenues for health insurers will continue growing, but enrollment will probably decline, according to a report issued by Corporate Research Group, a market research organization specializing in health care. Potential sources of growth for the industry include consumer-directed health care, which is expected to account for 15 percent to 20 percent of health plan enrollment by the year 2010, more product diversification, including ancillary businesses that broaden product lines and create new revenue opportunities, consolidation, and Medicare. The Medicare Advantage market has rebounded since 2004, when enrollment rose 1.9 percent. The resurgence continued in 2005, with enrollment climbing by 10.2 percent. Medicare Advantage health plans will receive an increase of 4.8 percent per plan enrollee in 2006. That follows a 6.6 percent hike in 2005.

When the accounting books have closed for 2006, the managed care industry is projected to report increased revenue of 9.1 percent, to a total of $287 billion. At the same time, profit margins will have expanded 5.8 percent, up from 5.5 percent in 2005. In addition, fully funded HMO and POS membership will continue to decline, but at a slower rate, dropping 0.1 percent in 2006, compared to 0.4 percent in 2005.

To purchase the 2007 edition of the Outlook for Managed Care Report, please contact Reena Joseph, Corporate Research Group, at 914-235-6000.

Forecast managed care industry percentage growth, 2005–2008

Forecast managed care industry revenue and profit growth, 2005–2008 ($ in millions)

Managed Care’s Top Ten Articles of 2016

There’s a lot more going on in health care than mergers (Aetna-Humana, Anthem-Cigna) creating huge players. Hundreds of insurers operate in 50 different states. Self-insured employers, ACA public exchanges, Medicare Advantage, and Medicaid managed care plans crowd an increasingly complex market.

Major health care players are determined to make health information exchanges (HIEs) work. The push toward value-based payment alone almost guarantees that HIEs will be tweaked, poked, prodded, and overhauled until they deliver on their promise. The goal: straight talk from and among tech systems.

They bring a different mindset. They’re willing to work in teams and focus on the sort of evidence-based medicine that can guide health care’s transformation into a system based on value. One question: How well will this new generation of data-driven MDs deal with patients?

The surge of new MS treatments have been for the relapsing-remitting form of the disease. There’s hope for sufferers of a different form of MS. By homing in on CD20-positive B cells, ocrelizumab is able to knock them out and other aberrant B cells circulating in the bloodstream.

A flood of tests have insurers ramping up prior authorization and utilization review. Information overload is a problem. As doctors struggle to keep up, health plans need to get ahead of the development of the technology in order to successfully manage genetic testing appropriately.

Having the data is one thing. Knowing how to use it is another. Applying its computational power to the data, a company called RowdMap puts providers into high-, medium-, and low-value buckets compared with peers in their markets, using specific benchmarks to show why outliers differ from the norm.
Competition among manufacturers, industry consolidation, and capitalization on me-too drugs are cranking up generic and branded drug prices. This increase has compelled PBMs, health plan sponsors, and retail pharmacies to find novel ways to turn a profit, often at the expense of the consumer.
The development of recombinant DNA and other technologies has added a new dimension to care. These medications have revolutionized the treatment of rheumatoid arthritis and many of the other 80 or so autoimmune diseases. But they can be budget busters and have a tricky side effect profile.

Shelley Slade
Vogel, Slade & Goldstein

Hub programs have emerged as a profitable new line of business in the sales and distribution side of the pharmaceutical industry that has got more than its fair share of wheeling and dealing. But they spell trouble if they spark collusion, threaten patients, or waste federal dollars.

More companies are self-insuring—and it’s not just large employers that are striking out on their own. The percentage of employers who fully self-insure increased by 44% in 1999 to 63% in 2015. Self-insurance may give employers more control over benefit packages, and stop-loss protects them against uncapped liability.